B+
Bull case
25%
Probability
Target price
$14.00
-13.0% vs current
BDSX
BiodesixDNasdaq / Health Care Equipment & Services
Last Price
At close
2026-06-03
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+1Most likely
B
Base case
50%
Probability
Target price
$11.50
-28.6% vs current
B-
Bear case
25%
Probability
Target price
$8.00
-50.3% vs current
AI sentiment snapshot
Latest data as of 2026-05-04
Recent news sentiment (30D)
-26.5
Negative
Company
-
Unavailable
Macro
-26.5
Negative
Pulse
-
Unavailable
Sentiment proxy
+17.1
Score
AI commentary
As of May 4, 2026, this remains a monitoring-style earnings follow-up rather than a confirmed post-print thesis update. Primary company sources confirmed the scheduled May 4, 2026 after-close release and 4:30 p.m. EDT earnings call, but did not yet provide the actual Q1 2026 results package during this review window [#IR-2026-04-20] [#IR-2026-05-04]. That means revenue/EPS surprise data, analyst revisions, and true market reaction were unavailable, so the deterministic prior appropriately shifts the stance back toward neutral and lower-conviction.
RankAlpha Sentiment Codex - 2026-05-04
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-05-04eventMay 4, 2026 earnings release is still the immediate gating eventHigh impact
Biodesix said on April 20, 2026 that it would report first-quarter 2026 results after the close on May 4, 2026 and host a 4:30 p.m. EDT call the same day, but as of this review the company’s investor pages still showed the event rather than an actual Q1 release or updated quarterly-results posting. That leaves the core earnings surprise, guidance confirmation, and initial management commentary unresolved for this run [#IR-2026-04-20] [#IR-2026-05-04].
2026-06-30catalystBalance-sheet relief improved but financing overhang still mattersHigh impact
The prior filing set showed cash support improving through year-end 2025, including pro forma cash aided by subsequent ATM proceeds and an amended Perceptive term loan extending maturity to November 2028, which reduced near-term solvency pressure. Even so, the capital structure still leaves dilution and cash-burn sensitivity as important constraints for a micro-cap diagnostics story [#8-K-2026-02-26] [#10-K-2026-02-26].
2026-12-31catalystNodify adoption and payer coverage remain the main strategic upsideHigh impact
The durable upside case still depends on continued Nodify Lung adoption, higher test volume, better average revenue per test, and further payer support rather than on a single binary event. That was the central operating driver in the prior baseline and remains the best long-duration re-rating path if 2026 execution stays on track [#10-K-2026-02-26] [#8-K-2026-02-26].
Recommendation
N/A
No formal recommendation provided.
As of 2026-05-04 • Updated nightlySource: Internal modelMethodology